FEATURED EDITORIAL
With a focus on small molecule drug product manufacture, let's take a closer look at the efficiencies gained through closed-loop control, PAT, digital twins, and more.
- Your CDMO Can Make It, But Can Your Market Afford It?
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- CDMO Selection Beyond Capabilities And Price
- August 2026 — CDMO Opportunities And Threats Report
- Dr. Heidi Overton And The FDA: An Outsourcing Perspective
- Building Sustainable Biopharma Supply Chains Starts With Procurement
- FDA Not A Good FRAME for CDMO Inspections?
GUEST COLUMNISTS
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
CDMO Selection Beyond Capabilities And Price
Some of the most useful information relevant to CDMO selection is also the hardest to obtain. Here are suggestions for uncovering data that tells the whole capability story.
-
August 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Building Sustainable Biopharma Supply Chains Starts With Procurement
Nearly all the industry's emissions happen upstream from core manufacturing functions. This puts sustainability almost entirely on the shoulders of purchasing.
-
Why You Should Measure Comparability Debt Before Ever Starting A Study
When analytical capability and process understanding fail to keep pace with a drug candidate, the technical uncertainty creates debt that's difficult to pay down.
-
What FDA Inspectors Want From Your OOS File
Read enough FDA warning letters and a pattern emerges: Investigators rarely cite a retest that was performed badly. They cite a retest that nobody justified in writing. Let's take a closer look.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
AI Fills The Decision-Making Gaps In Process Analytical Technology
When combined, artificial intelligence and PAT help move beyond reactive quality testing to proactive and anticipatory process management.
PHARMA OUTSOURCING WHITE PAPERS
-
Better, Safer Science Through Proper Detergent Selection And Cleaning
Enforce reliable lab results by improving washer performance, detergent selection, and rinsing to prevent residues, cross-contamination, and spotting—supporting reproducibility and compliance.
-
Smart Scaling For Cell And Gene Therapies
To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.
-
IP Considerations In Drug Development For Biotech Companies
Integrate a strategic intellectual property approach early in drug development to streamline research, uncover opportunities, and maximize the return on your investment.
-
How Integration Is Redefining Speed, Scale, And Sustainability
Integrated manufacturing ecosystems help biologics programs adapt to changing demand across the product lifecycle. Discover flexible scaling strategies that improve speed, efficiency, and sustainability.
-
The Key To Viral Vector Success
Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing.
-
What FDA CRLs Reveal About E&L
FDA feedback shows E&L gaps still delay approvals. This preview flags common issues — from unknown compounds to weak tox data — and offers ways to strengthen E&L approaches and cut regulatory risk.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
- Controlling mAb Aggregates In Chromatography Process Development
- Accelerating Development Of A Unique Molecule To Treat Lung Cancer
- Improving Bioavailability Through Predictive Modeling Of Solubility Enhancement Strategies
- Best Practices For Oncolytic Virus Design, Development, Manufacturing
- Manufacturing Glycosylated Erythropoietin Without 𝛼1,3-Fucosylation
NEWSLETTER ARCHIVE
- 10.02.26 -- Navigating The Future Of Large-Volume Biologic Delivery
- 10.02.26 -- AI And Data Pull CDMOs Into Pharma's Commercial Strategy
- 10.01.26 -- New Podcast Episodes: 2026 Regulatory Updates, Funding A Virtual Biotech, Structuring CGT Deals
- 10.01.26 -- A Breast Cancer Vaccine Moves Prevention Closer To Reality
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Design Verification Done Right: Smarter Strategies For Prefillable Syringes
- Scaling Cell And Gene Therapy Manufacturing
- IND In As Little As 6 Months: Now Beyond mAbs - Accelerating Bispecifics, Fc-Fusions And High-Concentration Biologics To The Clinic
- Mastering The Path: Developing Processes For Successful Clinical-Grade mRNA Manufacturing
- De-Risking The Path To GMP Manufacturing At Another Organization